Shanghai Henlius Biotech Co. Ltd. has announced the successful completion of a Phase I/II clinical trial to assess the safety and preliminary efficacy of HLX04-O (bevacizumab), a recombinant anti-VEGF humanized monoclonal antibody injection jointly developed with Essex Bio-Technology Limited. HLX04-O has the potential to be one of the first bevacizumab products approved for ophthalmic diseases, an indication where it is currently used off-label.
The single-arm, open-label, multi-center study evaluated the safety and efficacy of the compound via intravitreal injection in patients with active wet age-related macular degeneration
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?